newsfilter
← Latest News
PR Newswire·

Curis Consents First Six Patients in TakeAim CLL Study

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...